

CeFUroxime

Contains a PENICILLIN-like structure

Form:	250mg, 750mg and 1.5 g dry powder vials
Reconstitution:	<u>Intravenous</u> Add at least 2ml WFI to 250mg vial. Add at least 6ml WFI to 750mg vial. Add 15ml WFI to 1.5g vial. <u>Intramuscular</u> Add 1ml WFI per 250mg powder.
Administration Method:	<u>IV Injection</u> Give slowly over 3 - 5 minutes. <u>IV Infusion</u> After reconstitution, dilute required dose in 50 - 100mL of compatible fluid. Infuse over 30 - 60 minutes. <u>IM injection</u> Not more than 750 mg should be injected at one site. For doses greater than 1.5 g intravenous administration should be used.
Compatibility & Stability:	Sodium Chloride 0.9% Glucose 5%

Information provided relates to Cefuroxime manufactured by Fresenius Kabi and GlaxoSmithKline.

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542